Skip to content

Share

  • Add this article to your LinkedIn page
  • Add this article to your Twitter feed
  • Add this article to your Facebook page
  • Email this article
  • View or print a PDF of this page
  • Share further
  • Add this article to your Pinterest board
  • Add this article to your Google page
  • Share this article on Reddit
  • Share this article on StumbleUpon
  • Bookmark this page
PA IN THE MEDIA

Gene Genius

PA Consulting’s Paul Stroemer, cell and gene therapy expert, comments on the development and use of innovative gene therapies to treat rare diseases in an article by Joy Persaud in Raconteur's Future of Healthcare report.

Read the full original article here

Commenting on the use of gene therapy for Retinitis Pigmentosa, Paul explains: “Retinal disorders are good candidates for gene therapy,” adding “Loss of tissue in the eye is gradual, giving a wide treatment window. Nerve cells in the eye don’t divide, meaning that there is no requirement for administering further treatments. The therapy is permanent – one and done.”

Paul continues, saying that one eye is treated at a time, which means the un-treated eye will note experience any adverse reactions.

Commenting on the use of gene therapy for Spinal Muscular Atrophy (SMA), Paul explains that: “Patients with this disease lack the survival motor neuron protein, which is essential for the normal functioning of motor neurons. Without it, these nerve cells deteriorate and eventually die,” adding that “Diagnosis can be made via gene screening, which can be done at birth.”

Explaining the procedure, Paul says: “When injected, it passes into the nerves and provides the correct gene to make enough of the protein and thereby restore nerve function.”

He adds: “Given that there were practically no other viable permanent treatment options available before, the significance of Zolgensma’s introduction as a treatment for SMA should not be underestimated.”

Our new report explores four potential future cell and gene therapy scenarios using our FutureWorlds™ approach

Read more here

Contact the life sciences team